UK trials for new skin cancer drug
A revolutionary new pill for advanced skin cancer that may offer new hope to people with resistant disease is to be trialled in the UK next year.
Laboratory tests suggest that the drug, known as a panRAF inhibitor, is likely to be effective in melanoma patients no longer responding to existing treatments.
It may also help people with a strain of cancer that cannot be treated with standard drugs.
Melanoma, or malignant skin cancer, affects around 13,000 people and causes more than 2,000 deaths in the UK each year.
The new drugs, which target a wider range of biological pathways, have been shown to halt the growth of resistant tumours.